New Data Shows ZORYVE Cream 0.3% Provided Measurable Improvement Of Plaque Psoriasis In Nearly All Individuals In DERMIS Trials
Portfolio Pulse from Benzinga Newsdesk
New data from the DERMIS trials shows that 95% of individuals treated with ZORYVE Cream 0.3% had a measurable improvement in Psoriasis Area and Severity Index (PASI) at Week 8. Over 85% achieved measurable improvement by Week 2. The data also confirms that ZORYVE is well tolerated according to both investigator and patient local tolerability assessments.
October 20, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the DERMIS trials for ZORYVE Cream 0.3% could potentially boost the stock of ARQT, the company that may be associated with the product.
The positive results from the DERMIS trials for ZORYVE Cream 0.3% indicate a successful product that is well tolerated by patients. This could lead to increased sales and revenue for the company associated with the product, potentially ARQT, which could in turn boost the company's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80